pubmed.ncbi.nlm.nih.gov

Increasing coverage and efficiency of measles, mumps, and rubella vaccine and introducing universal varicella vaccination in Europe: a role for the combined vaccine - PubMed

Review

Increasing coverage and efficiency of measles, mumps, and rubella vaccine and introducing universal varicella vaccination in Europe: a role for the combined vaccine

Timo Vesikari et al. Pediatr Infect Dis J. 2007 Jul.

Abstract

Universal mass vaccination according to a 2-dose measles-mumps-rubella (MMR) vaccine schedule is recommended by the World Health Organization and is fundamental to the control of these important diseases. Very high coverage (first dose, > or =95%; second dose, > or =80%) is necessary to achieve and sustain high population immunity, and eventually interrupt indigenous transmission of these diseases. In 2006, the Advisory Committee on Immunization Practices issued a recommendation for 2 doses of varicella vaccine to be given universally to children. Coadministration of MMR and varicella vaccines, though efficacious and well tolerated, can be difficult because of the 2 separate injections and associated compliance issues. In addition to the general advantages of a combined vaccine, recently registered measles-mumps-rubella-varicella (MMRV) vaccines could facilitate introduction of varicella universal mass vaccination by simplifying administration and providing the potential to achieve high coverage rates for these 4 diseases.

PubMed Disclaimer

Cited by

A network strategy to advance public health in Europe.
Semenza JC, Apfel F, Rose T, Giesecke J. Semenza JC, et al. Eur J Public Health. 2008 Oct;18(5):441-7. doi: 10.1093/eurpub/ckn019. Epub 2008 Jun 6. Eur J Public Health. 2008. PMID: 18539625 Free PMC article. No abstract available.
Immunogenicity and safety of early vaccination with two doses of a combined measles-mumps-rubella-varicella vaccine in healthy Indian children from 9 months of age: a phase III, randomised, non-inferiority trial.
Lalwani S, Chatterjee S, Balasubramanian S, Bavdekar A, Mehta S, Datta S, Povey M, Henry O. Lalwani S, et al. BMJ Open. 2015 Sep 11;5(9):e007202. doi: 10.1136/bmjopen-2014-007202. BMJ Open. 2015. PMID: 26362659 Free PMC article. Clinical Trial.
Safety, immunogenicity and immediate pain of intramuscular versus subcutaneous administration of a measles-mumps-rubella-varicella vaccine to children aged 11-21 months.
Knuf M, Zepp F, Meyer CU, Habermehl P, Maurer L, Burow HM, Behre U, Janssens M, Willems P, Bisanz H, Vetter V, Schmidt-Ott R. Knuf M, et al. Eur J Pediatr. 2010 Aug;169(8):925-33. doi: 10.1007/s00431-010-1142-6. Epub 2010 Feb 11. Eur J Pediatr. 2010. PMID: 20148263 Clinical Trial.
Public awareness regarding children vaccination in Jordan.
Masadeh MM, Alzoubi KH, Al-Azzam SI, Al-Agedi HS, Abu Rashid BE, Mukattash TL. Masadeh MM, et al. Hum Vaccin Immunother. 2014;10(6):1762-6. doi: 10.4161/hv.28608. Epub 2014 May 7. Hum Vaccin Immunother. 2014. PMID: 24732060 Free PMC article.
Vaccines for measles, mumps, rubella, and varicella in children.
Di Pietrantonj C, Rivetti A, Marchione P, Debalini MG, Demicheli V. Di Pietrantonj C, et al. Cochrane Database Syst Rev. 2021 Nov 22;11(11):CD004407. doi: 10.1002/14651858.CD004407.pub5. Cochrane Database Syst Rev. 2021. PMID: 34806766 Free PMC article. Review.

Increasing coverage and efficiency of measles, mumps, and rubella vaccine and introducing universal varicella vaccination in Europe: a role for the combined vaccine - PubMed